Trial Profile
A Multicenter, Open-label, Randomized, Event-driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan Versus Standard of Care in Children With Pulmonary Arterial Hypertension
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics; Registrational
- Acronyms TOMORROW
- Sponsors Actelion Pharmaceuticals
- 01 Feb 2024 Planned End Date changed from 8 Sep 2024 to 29 Feb 2024.
- 10 Oct 2023 Planned End Date changed from 29 Feb 2024 to 8 Sep 2024.
- 10 Oct 2023 Planned primary completion date changed from 29 Feb 2024 to 23 Dec 2024.